AAV ℞: Induction


Rituximab Effective for Children, Adolescents With Granulomatosis With Polyangiitis, Microscopic Polyangiitis


Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis


Rituximab treatment in AAV is associated with about 25% of cases having serious infections, especially during induction treatment of active disease. The infection risk can be up to 6-fold higher in those with lung involvement in AAV, and those with underlying lung comorbidities. Bactrim prophylaxis can reduce infection risk by 70%.